GLP-1 does not acutely affect insulin sensitivity in healthy man

Diabetologia

Volumn 39, Issue 10, 1996, Pages 1227-1232

  Orskov L ^a   Holst, J J ^b   Moller J ^a   Orskov C ^b   Moller N ^a   Alberti, K G M M ^c   Schmitz, O ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Clamp; Glucagon like peptide 1; Glucose metabolism; Insulin sensitivity; Non insulin dependent diabetes mellitus

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; SOMATOSTATIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; INSULIN SENSITIVITY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0029745122     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02658511     Document Type: Article

References (32)

1. Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 2: 1300-1304
2. Ørskov C (1992) Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35: 701-711
3. Ørskov C, Holst JJ, Nielsen OV (1988) Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology 123: 2009-2013
4. Herrmann C, Goke R, Richter G, Fehmann HC, Arnold R, Goke B (1995) Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients. Digest 56: 117-126
5. Gutniak M, Ørskov C, Holst JJ, Ahren B, Efendic S (1992) Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. N Engl J Med 326: 1316-1322
6. Nathan DM, Schreiber E, Fogel H, Mosjov S, Habener JF (1992) Insulinotropic action of glucagonlike peptide-I-(7-37) in diabetic and nondiabetic subjects. Diabetes Care 15: 270-276
7. Nauck MA, Heimesaat MM, Ørskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91: 301-307
8. Nauck MA, Kleine N, Ørskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36: 741-744
9. Hvidberg A, Nielsen MT, Hilsted J, Ørskov C, Holst JJ (1994) Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man. Metabolism 43: 104-108
10. Villanueva Pañacarrillo ML, Alcántara AI, Clemente F, Delgado E, Valverde I (1994) Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37: 1163-1166
11. Delgado E, Luque MA, Alcantara A et al. (1995) Glucagon-like peptide-1 binding to rat skeletal muscle. Pept 16: 225-229
12. Frayn KN (1983) Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 55: 628-634
13. Ørskov C, Jeppesen J, Madsbad S, Holst JJ (1991) Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine. J Clin Invest 87: 415-423
14. Ørskov C, Rabenhøj L, Wettergren A Kofod H, Holst JJ (1994) Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes 43: 535-539
15. Andersen L, Dinesen B, Jørgensen PN, Poulsen F, Roder ME (1993) Enzyme immunoassay for intact human insulin in serum or plasma. Clin Chem 39: 578-582
16. Harrison J, Hodson AW, Skillen AW, Stappenheck R, Agius L, Alberti KG (1988) Blood glucose, lactate, pyruvate, glycerol, 3-hydroxyhutyrate and acetoacetate measurements in man using a centrifugal analyser with a fluorimetric attachment. J Clin Chem Clin Biochem 26: 141-146
17. Ørskov L, Bak JF, Abildgård N, et al. (1996) Inhibition of muscle glycogen synthase activity and non-oxidative glucose disposal during hypoglycaemia in normal man. Diabetologia 39: 226-234
18. Finegood DT, Bergman RN, Vranic M (1987) Estimation of endogenous glucose production during hyperinsulinemic-euglycemic glucose clamp. Diabetes 36: 914-924
19. Gutniak MK, Linde B, Holst JJ, Efendic S (1994) Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17: 1039-1044
20. Ritzel R, Ørskov C, Holst JJ, Nauck MA (1995) Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 (7-36 amide) after subcutaneous injection in healthy volunteers. Dose-response-relationships. Diabetologia 38: 720-725
21. Weir GC, Mosjov S, Hendrick GK, Habener JF (1989) Glucagon-like peptide (7-37) actions on endocrine pancreas. Diabetes 38: 338-342
22. D'Alessio DA, Kahn SE, Leusner CR, Ensinck JW (1994) Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal. J Clin Invest 93: 2263-2266
23. D'Alessio A, Prigeon RL, Ensinck JW (1995) Enteral enhancement of glucose disposition by both insulin-dependent and insulin-independent processes. Diabetes 44: 1433-1437
24. Toft-Nielscn M, Madsbad S, Holst JJ (1995) The effect of GLP-1 on glucose elimination. Diahetologia 38: A655 (Abstact)
25. Wheeler MB, Lu M, Dillon JS, Leng HX, Chen C, Boyd AE III (1993) Functional expression of the rat glucagon-like peptide-1 receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C. Endocrinology 133: 57-62
26. Valverde I, Morales M, Clemente Fet al. (1994) Glucagon-like peptide 1: a potent glycogenic hormone. FEBS Lett 349: 313-316
27. Furnsinn C, Ebner K, Waldhausl W (1995) Failure of glucagon-like peptide-1(7-36)amide to affect glycogenesis in rat skeletal muscle. Diabetologia 38: 864-867 (Abstact)
28. Freyse EJ, Knospe S, El-Hag O, Becher T, Fischer U, Goke B (1995) Does glucagon-like peptide-I affect the catabolic effects of glucagon in the insulin deficient state? Diabetologia 38: A645 (Abstract)
29. Groop LC, Widén E, Ferrannini E (1993) Insulin resistance and insulin defiency in the pathogenusis of type 2 (non-insulin-dependent) diabetes mellitus: errors of metabolism or methods. Diabetologia 36: 1326-1331
30. Holst JJ (1994) Glucagonlike peptide 1: a newly discovered gastrointestinal hormone. Gastroenterology 107: 1848-1855
31. Oben J, Morgan L, Fletcher J, Marks V (1991) Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1 (7-36) amide, on fatty acid synthesis in explants of rat adipose tissue. J Endocrinol 130: 267-272
32. Ruiz Grande C, Alarcon C, Merida E, Valverde I (1992) Lipolytic action of glucagon-like peptides in isolated rat adipocytes. Pept 13: 13-16